At OCT Clinical, we are proud to advance sponsors’ clinical development goals while upholding the highest standards of regulatory adherence, environmental responsibility, and patient care.
OCT Clinical has always adhered to the principles of running a sustainable business, standing by its set of values as well as retaining and contributing to the environment. Our goal is to establish lasting values and core principles, create excellent working conditions and give back to the community.
Through our Corporate Social Responsibility program we strive to ensure that not only our operations leave a minimal footprint on the environment and the community, but that we also manage to create value and positive change outside the scope of our primary business processes.
Realizing the immediate role of research in combating serious diseases, OCT Clinical is proud to be an oncology CRO supporting independent scientists who rigorously work on finding effective ways to cure cancer. One such organization is The Foundation for Cancer Research Support (RakFond) where OCT Clinical transfers part of its revenue to contribute to the research and stimulate profound discoveries.
Another initiative launched within the company is placing orders for corporate stationery through a vendor which forwards the funds to the AdVita Cancer Fund, which helps children battling cancer.
While watching and minimizing OCT Clinical’s overall footprint, the company has been vigorously working on creating a sustainable environment within the offices as well. To that end a series of initiatives has been incorporated across all of the offices of OCT Clinical:
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
